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Abstract
Several models have been described as potential mechanisms for the progression of ductal carcinoma in situ (DCIS) to invasive
breast cancer (IBC). The aim of our study was to increase our understanding of DCIS progression by using massive parallel
sequencing of synchronous DCIS and IBC. We included patients with synchronous DCIS and IBC (n = 4). Initially, IBC and
normal tissue were subjected to whole exome sequencing. Subsequently, targeted sequencing was performed to validate those
tumor-specific variants identified by whole exome sequencing. Finally, we analyzed whether those specific variants of the
invasive component were also present in the DCIS component. There was a high genomic concordance between synchronous
DCIS and IBC (52 out of 92 mutations were present in both components). However, the remaining mutations (40 out of 92) were
restricted to the invasive component. The proportion of tumor cells with these mutations was higher in the invasive component
compared to the DCIS component in a subset of patients. Our findings support the theory that the progression from DCIS to IBC
could be driven by the selection of subclones with specific genetic aberrations. This knowledge improves our understanding of
DCIS progression, which may lead to the identification of potential markers of progression and novel therapeutic targets in order
to develop a more personalized treatment of patients with DCIS.
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Ductal carcinoma in situ (DCIS) is a non-obligate precursor of
invasive breast cancer (IBC). However, no reliable biomarkers
or clinical tests are available to predict which DCIS cases are
most likely to progress. In-depth genetic studies of DCIS and
synchronous IBC reported intra-tumoral genetic heterogeneity
and genetic differences between DCIS and synchronous IBC
[1, 2]. Based on these findings, an evolutionary bottleneck
selection model has been proposed [3, 4]. According to this
theory, distinct subclones with specific genetic changes are
selected during the transition from DCIS to invasive disease.
This leads to differences in the prevalence of specific muta-
tions between the neoplastic DCIS cells and invasive counter-
part [3, 5, 6]. In contrast to this model, a multiclonal evolution
theory has been proposed, which assumes that multiple
subclones in DCIS co-migrate during the transition from
DCIS to IBC [4, 7]. To increase our understanding of DCIS
progression, we performed massive parallel sequencing of
synchronous DCIS and IBC. We reported overlapping muta-
tions between synchronous DCIS and IBC combined with the
presence of invasive-specific mutations, which support the
theory that the progression from DCIS to IBC could be driven
by the selection of subclones with specific genetic aberrations.
We examined the exomes of four patients diagnosed with
estrogen receptor (ER) positive, human epidermal growth fac-
tor receptor 2 (HER2) negative DCIS, and synchronous IBC
after surgical excision. All cases had an invasive ductal carci-
noma that was graded in each case as grade 3. Regarding the
in situ component, the DCIS grade was in all cases concordant
with the grade of the invasive carcinoma. The proportion of
DCIS in each case was ranging from 2 to 5 cm.
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Figure 1 provides an overview of the workflow. Initially,
fresh frozen (FF) tissue of IBC and normal cells were subjected
to whole exome sequencing. The sequence reads were aligned
to the human genome build 19 (hg19) using BWA [8]. For
each sample, at least four gigabases of sequences were aligned
to the genome with an average coverage of at least 120× for
IBC and at least 70× for normal tissue samples. Subsequently,
the aligned reads were processed using the Indel Realigner,
Mark Duplicates, and PHRED Recalibration tools from the
Genome Analysis Toolkit (GATK) [9] to remove systematic
biases and to recalibrate the PHRED quality scores in the align-
ments. Genetic variants were called using the Unified
Genotyper Tool from GATK.
Based on the selected invasive tumor-specific variants, a
specific custom-made panel was designed per patient. This
custom-made cancer panel was performed on the Ion Torrent
Personal GenomeMachine (PGM) in order to validate wheth-
er those tumor-specific variants identified by whole exome
sequencing could also be detected by targeted sequencing,
using the same FF DNA samples, to ensure an accurate con-
cordance between these two platforms. Subsequently, IBC-
specific variants verified by Ion Torrent PGM were validated
in DNA of formalin-fixed paraffin-embedded (FFPE) tissue of
IBC, using a minimal genomic DNA input of 10 ng. In the
final step, we validated only those IBC-specific variants ver-
ified in both FF tissue and FFPE tissue of IBC on DNA ex-
tracted from FFPE tissue of DCIS.
Library and template preparations were performed consec-
utively with the AmpliSeq Library Kit 2.0-384 LVand the Ion
PGMHi-Q Chef Kit. Templates were sequenced using the Ion
PGM Hi-Q Chef Kit on an Ion 318v2 chip. Sequence infor-
mation was analyzed with Variant Caller v4.4.2.1 (Life
Fig. 1 Schematic overview of the
DNA-sequencing process from
whole exome sequencing to
targeted NGS
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Technologies Carlsbad, CA, USA), and variants were anno-
tated in a local Galaxy pipeline using ANNOVAR [10].
Variants were called when the position was covered at least
100 times. Non-synonymous somatic point mutations, inser-
tions, and deletions that change the protein amino acids se-
quence and splice site alterations were selected. Variants
Fig. 2 Differences in tumor specific-variant percentages between DCIS (square) and adjacent IBC (rhomb) in all four patients
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found in at least 5% of the called reads and ≥ 10 variant-reads
were considered reliable.
Based on whole exome sequencing of the four IBC sam-
ples, a total number of 792 tumor-specific variants were iden-
tified. Out of these 792 tumor-specific variants, primers were
available for 585 variants. In total, 433 out of 585 tumor-
specific variants could not be verified as a tumor-specific var-
iant at the (Ion Torrent) validation stage in FF tissue of IBC.
Out of the remaining 152 tumor-specific variants, 60 variants
could not be validated in FFPE tissue of IBC. These variants
were excluded for further analysis.
This resulted in a total number of 92 tumor-specific vari-
ants that remained for targeted validation in the DCIS compo-
nent. Within each patient, a proportion of tumor-specific var-
iants overlapped between the DCIS component and the inva-
sive counterpart (in total 52 out of 92). In patient 1, all tumor-
specific variants (17 out of 17) that were identified in IBC
were also detected in the DCIS component. In the remaining
three patients, the number of tumor-specific variants detected
in the DCIS component was lower compared to the number
detected in the invasive component.
We also compared the frequencies of tumor-specific vari-
ants between DCIS and adjacent IBC, as shown in Fig. 2. In
patient 1, the frequency of tumor-specific variants was higher
in the invasive component as compared to the DCIS compo-
nent, which could not be explained by a difference in tumor
cell percentage. This trend was also seen in patient 2, although
less tumor-specific variants were detected as compared to pa-
tient 1. In patient 3, there was no consistent pattern with re-
spect to differences in the distribution of tumor-specific vari-
ant percentages between the two components. For patient 4,
there were only four overlapping tumor-specific variants be-
tween the invasive component and the in situ component. This
patient showed a higher frequency of tumor-specific variants
in DCIS as compared to IBC for three out of the four
mutations.
Taken together, our analyses confirmed a high genomic
resemblance between synchronous DCIS and IBC; more than
half (52 out of 92) of the mutations identified in the invasive
component were also detected in the adjacent in situ compo-
nent. However, a proportion of mutations (40 out of 92) iden-
tified in IBC were not detected in the adjacent DCIS compo-
nent. In addition, in a subset of patients, the frequencies of the
mutations seemed to be higher in the invasive component as
compared to DCIS, which could not be explained by the tu-
mor cell percentages in the analyses.
It is important to note that these findings are based on a
small number of patients and should be considered as a gen-
erated hypothesis only. Besides, our study has several other
limitations. First of all, we used two different platforms of
massive parallel sequencing. At the validation stage, major
differences were observed between these two platforms, due
to unreadable sequence regions by Ion Torrent, an insufficient
number of reads and false-positive tumor-specific variants
(validated in normal tissue by Ion Torrent sequencing). The
latter might be the result of a lower sequence depth of whole
exome sequencing as compared to Ion Torrent sequencing. In
addition, a substantial proportion of variants detected in FF
tissue of IBC using Ion Torrent sequencing could not be de-
tected in FFPE tissue of the same tumor, which could be due to
tumor heterogeneity. Another limitation of this study is the
lack of whole exome data for DCIS, due to lack of available
FF tissue of DCIS. Therefore, we could only perform a one-
way evaluation of genetic alterations between synchronous
DCIS and IBC; genetic alterations restricted to the DCIS com-
ponent could not be evaluated. At last, we only included ER
positive/HER2-negative breast cancer.
In conclusion, we reported overlapping mutations between
synchronous DCIS and IBC (with differences regarding the
frequencies of mutations between both components), com-
bined with the presence of invasive-specific mutations, which
support the theory that DCIS progression could be driven by
the selection of subclones. This knowledge might facilitate
future studies regarding potential progression markers and
novel therapeutic targets in order to establish a more effective
personalized treatment for patients with DCIS.
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